Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy.

Autor: Cui Y; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.; Division of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China., Chen Y; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Zhao P; Translational Oncology Research Lab, Jilin Cancer Hospital, Changchun, China., Li S; Big Data Center of Clinical, Jilin Cancer Hospital, Changchun, China., Cheng Y; Division of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China. chengying@csco.org.cn., Ren X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China. renxiubao@tjmuch.com.; Tianjin's Clinical Research Center for Cancer, Tianjin, China. renxiubao@tjmuch.com.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. renxiubao@tjmuch.com.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. renxiubao@tjmuch.com.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Oct; Vol. 26 (10), pp. 2522-2530. Date of Electronic Publication: 2024 Apr 25.
DOI: 10.1007/s12094-024-03479-4
Abstrakt: Purpose: Although immunotherapy improves outcomes in extensive-stage small-cell lung cancer (ES-SCLC), the search for biomarkers predicting treatment success is crucial. Natural killer (NK) cells are potential indicators in various cancers, however, their precise role in ES-SCLC prognosis remains unclear.
Methods: In this retrospective study, 33 patients with ES-SCLC treated with first-line immuno-chemotherapy were enrolled. The peripheral NK cell percentage and its longitudinal dynamics were analyzed using flow cytometry. Progression-free survival (PFS) and overall survival (OS) were calculated as hazard ratio (HR) and compared statistically.
Results: The median PFS was better in the group with normal baseline NK cell levels than the low group (7.0 vs. 4.6 months; HR = 0.17; 95% CI 0.07-0.41; P < 0.0001), but there was no association with OS (14.9 vs. 10.3 months; HR = 0.55; 95% CI 0.23-1.31; P = 0.171). Furthermore, the NK cell% for 95.0% of patients increased after immunochemotherapy in the clinical response group (P = 0.0047), which led to a better median PFS (6.3 vs. 2.1 months; HR = 0.23; 95% CI 0.05-0.98; P < 0.0001) and OS (14.9 vs. 5.9 months; HR = 0.20; 95% CI 0.04-1.02; P < 0.0001). Similar trends were observed with NK cell% changes up to disease progression, improving PFS (6.5 vs. 4.3; HR = 0.41; 95% CI 0.12-0.92; P = 0.0049) and OS (17.4 vs. 9.7; HR = 0.42; 95% CI 0.17-1.02; P < 0.0001).
Conclusion: In patients with ES-SCLC, the percentage and changes in peripheral NK cells can predict the response to combined immunotherapy and chemotherapy.
(© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
Databáze: MEDLINE
Externí odkaz: